Table 1.
Cohort characteristics for women eligible for treatment according to SvOS, NOF and NOGG guidelines
| SvOS | NOF | NOGG | ||||
|---|---|---|---|---|---|---|
| Not eligible for treatment (n = 1876) | Eligible for treatment (n = 1107) | Not eligible for treatment (n = 572) | Eligible for treatment (n = 2411) | Not eligible for treatment (n = 1285) | Eligible for treatment (n = 1698) | |
| Age, years | 77.7 ± 1.6 | 78.0 ± 1.6c | 77.5 ± 1.6 | 77.8 ± 1.6c | 77.6 ± 1.6 | 77.9 ± 1.6c |
| Height, cm | 162.5 ± 5.7# | 160.8 ± 6.2£c | 163.4 ± 5.8€ | 161.5 ± 5.9$c | 162.4 ± 5.7‰ | 161.4 ± 6.0¢c |
| Weight, kg | 71.2 ± 12.1 | 64.6 ± 10.9c | 75.5 ± 13.0 | 67.1 ± 11.3c | 70.3 ± 12.4 | 67.6 ± 11.7c |
| Body mass index, kg/m2 | 27.0 ± 4.5 | 25.0 ± 4.0c | 28.3 ± 4.9 | 25.8 ± 4.1 | 26.7 ± 4.6 | 25.9 ± 4.2c |
| FRAX-score, MOF (%) | 18.0 ± 7.6 | 31.5 ± 12.8c | 12.4 ± 4.2 | 25.5 ± 11.6c | 14.0 ± 3.3 | 29.8 ± 11.4c |
| FRAX-score, HIP (%) | 7.2 ± 6.9 | 17.4 ± 13.6c | 3.0 ± 2.8 | 12.9 ± 11.4c | 4.4 ± 2.2 | 16.0 ± 12.4c |
| Prior fracture, n (%) | 420 (22.4) | 680 (61.4)c | 111 (19.4) | 989 (41.0)c | 0 (0) | 1100 (64.8)c |
| Rheumatoid arthritis, n (%) | 72 (3.8)† | 44 (4.0)¶ | 24 (4.2)€ | 92 (3.8)ø | 36 (2.8)¥ | 80 (4.7)∆b |
| Heredity of hip fracture, n (%) | 305 (16.3) | 211 (19.1) | 66 (11.5) | 450 (18.7)c | 51 (4.0) | 465 (27.4)c |
| Excessive alcohol consumption, n (%) | 8 (0.4) | 7 (0.6) | 4 (0.7) | 11 (0.5) | 4 (0.3) | 11 (0.6) |
| Current smoker, n (%) | 89 (4.7)Ω | 65 (5.9) | 20 (3.5) | 134 (5.6)∞a | 53 (4.1)‰ | 101 (5.9)a |
| Glucocorticoid treatment, n (%) | 0 (0.0) | 99 (8.9)c | 18 (3.1) | 81 (3.4) | 16 (1.2) | 83 (4.9)c |
| Diabetes, n (%) | 210 (11.2) | 81 (7.3)c | 76 (13.3) | 215 (8.9)b | 148 (11.5) | 143 (8.4)b |
| Femoral neck aBMD | 0.70 ± 0.09 | 0.59 ± 0.09c | 0.82 ± 0.07 | 0.62 ± 0.08c | 0.72 ± 0.10 | 0.62 ± 0.09c |
| T-score femoral neck | ||||||
| > −1.0 | 579 (30.9) | 64 (5.8) | 549 (96.0) | 94 (3.9) | 450 (35.0) | 193 (11.4) |
| − 1.0 to − 2.49 | 1297 (69.1) | 602 (54.4) | 23 (4.0) | 1876 (77.8) | 833 (64.8) | 1066 (62.8) |
| ≤ − 2.5 | 0 (0) | 441 (39.8) | 0 (0) | 441 (18.3) | 2 (0.2) | 439 (25.9) |
| Use of osteoporotic drug | ||||||
| Bisphosphonates, n (%) | 71 (3.8) | 215 (19.4) | 11 (1.9) | 275 (11.4) | 49 (17.1) | 237 (14.0) |
| Zoledronic acid, n (%) | 4 (0.2) | 19 (1.7) | 1 (0.2) | 22 (0.9) | 2 (0.2) | 21 (1.2) |
| Denosumab, n (%) | 1 (0.1) | 22 (2.0) | 0 (0) | 23 (1.0) | 2 (0.2) | 21 (1.2) |
Continuous variables are presented by mean ± SD and were compared by independent samples t test. Dichotomous variables are presented as number of subjects and percentage and differences were analyzed by the chi square test. Excessive alcohol consumption = 21 drinks or more per week. Glucocorticoid treatment = treatment with 5 mg per oral prednisolone or equal for more than 3 months, diabetes, defined by physician diagnosis
SvOS Swedish osteoporosis society guidelines, NOF National Osteoporosis Foundation, NOGG National Osteoporosis Guideline Group, SD standard deviation, aBMD areal bone mineral density, FRAX fracture risk assessment tool, MOF major osteoporotic fracture, HIP hip fracture. Each column presents the maximum number of participants and deviations are denoted for each variable by the following: ∞ = 2410, ø = 2408, $ = 2405, ¢ = 1692, Ω = 1875, # = 1874, † = 1873, ‰ = 1284, ¥ = 1283, ∆ = 1696, ¶ = 1106, £ = 1102, € = 571. A p value below 0.05 was considered significant
ap value < 0.05
bp value < 0.01
cp value < 0.001